HomeCompareCKSNF vs MRK

CKSNF vs MRK: Dividend Comparison 2026

CKSNF yields 7.09% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CKSNF wins by $48254.31M in total portfolio value
10 years
CKSNF
CKSNF
● Live price
7.09%
Share price
$4.42
Annual div
$0.31
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$48254.36M
Annual income
$46,981,087,354.03
Full CKSNF calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CKSNF vs MRK

📍 CKSNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCKSNFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CKSNF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CKSNF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CKSNF
Annual income on $10K today (after 15% tax)
$602.50/yr
After 10yr DRIP, annual income (after tax)
$39,933,924,250.93/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CKSNF beats the other by $39,933,915,922.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CKSNF + MRK for your $10,000?

CKSNF: 50%MRK: 50%
100% MRK50/50100% CKSNF
Portfolio after 10yr
$24127.21M
Annual income
$23,490,548,576.08/yr
Blended yield
97.36%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CKSNF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
4.1
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CKSNF buys
0
MRK buys
0
No recent congressional trades found for CKSNF or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCKSNFMRK
Forward yield7.09%2.76%
Annual dividend / share$0.31$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%32.7%
Portfolio after 10y$48254.36M$56.8K
Annual income after 10y$46,981,087,354.03$9,798.13
Total dividends collected$48166.94M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellBuy

Year-by-year: CKSNF vs MRK ($10,000, DRIP)

YearCKSNF PortfolioCKSNF Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,118$1,417.65$11,206$366.19+$912.00CKSNF
2$16,177$3,210.94$12,650$502.35+$3.5KCKSNF
3$25,321$8,012.24$14,407$694.19+$10.9KCKSNF
4$50,536$23,442.03$16,585$967.82+$34.0KCKSNF
5$141,522$87,448.75$19,342$1,363.89+$122.2KCKSNF
6$609,174$457,745.32$22,913$1,947.19+$586.3KCKSNF
7$4,334,690$3,682,874.11$27,662$2,823.89+$4.31MCKSNF
8$53,621,610$48,983,490.92$34,159$4,173.35+$53.59MCKSNF
9$1,189,978,134$1,132,603,011.20$43,337$6,308.80+$1189.93MCKSNF
10$48,254,363,957$46,981,087,354.03$56,776$9,798.13+$48254.31MCKSNF

CKSNF vs MRK: Complete Analysis 2026

CKSNFStock

Vesuvius plc provides engineering services and solutions principally to steel and foundry industries worldwide. It operates in two divisions, Steel and Foundry. The company offers foundry consumables and equipment, including binders, coatings, feeding systems, filtration and gating systems, melt shop refractories, metallurgical and pouring control systems, die dressings and coatings, melt treatment products, crucibles, and ceramics for the iron, steel, and nonferrous foundries. It also provides nonferrous metals, such as primary and secondary aluminum, copper, and other metals and alloys; cement and lime solutions, iron ore pelletizing and calcination products, and grains and powders; and process heaters, FCC units, hydrogen reformers, boilers, coke calciners, and thermal oxidizers, as well as sulphur, ethylene, and ammonia plants. In addition, the company offers solutions for power generation and incineration; glass products comprising artistic, display, float, hollow, and optical glass; glass tempering, and reheat and forming products; and solutions for solar multicrystal silicon ingots, thin film and cell processing, and feedstock. Further, it provides solutions for blast furnace stack repair; taphole clay, iron and slang runner, sampler and temperature, tilting runner, and torpedo ladle solutions; iron ladle solutions; lining, taphole system, bath agitation and tuyere system, electric arc furnace and BOF maintenance, and metallurgical sensor solutions; and ladle, ladle to tundish, and tundish solutions, as well as tundish to mold solutions for conventional slab, thin and slim slab, beam blank, flow control valve bloom or billet, and calibrated nozzle billet casters. Additionally, the company offers ingot casting solutions; and reheat furnace, steel hot forming, galvanized steel, and electrical and stainless-steel solutions. Vesuvius plc was founded in 1916 and is headquartered in London, the United Kingdom.

Full CKSNF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CKSNF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CKSNF vs SCHDCKSNF vs JEPICKSNF vs OCKSNF vs KOCKSNF vs MAINCKSNF vs JNJCKSNF vs ABBVCKSNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.